There are times in a medicine’s lifecycle when a pharmaceutical or biotech company must consider making it available as an unlicensed medicine outside the usual commercial channels.
This may be because they want or need to launch their medicine much later in some countries, and not at all in others.
It may be due to an unexpected disruption in the supply chain, or a pharmaceutical company withdrawing from a market or markets.
Ensuring access at these times is often outside the company’s core capabilities. They need a trusted partner to maintain highest standards of compliance and ethics while continuing to drive value – for themselves, for healthcare professionals and for patients.
A comprehensive understanding of the commercial vision is vital for the partner to develop a solution specific to their needs, no matter how complex.
That’s where a Clinigen partnership starts.
This essential first step allows clients to realise the full value of Clinigen’s expertise and insights in unlicensed medicines gained over 30 years on every continent.
Expertise that guides them in what’s feasible and what’s not. Insights that inform recommendations to add maximum value. And the reach, capacity and capability to deliver global access, supported by first-class logistics, customer service and regulatory know-how.
Clinigen’s approach ensures flexible solutions when and where clients and your patients need them.